Skip to content

Study · In vitro (cells) · 2002

7 results

The antiproliferative effect of synthetic peptidyl GH secretagogues in human CALU-1 lung carcinoma cells.

Ghè C, Cassoni P, Catapano F, Marrocco T, Deghenghi R, Ghigo E, Muccioli G, Papotti M

Endocrinology1 Feb 2002Cited by 76 (Europe PMC)

PMID11796502 (opens in a new tab)DOI10.1210/endo.143.2.8654 (opens in a new tab)PepBankPUB-11796502
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In CALU-1 lung carcinoma cells, hexarelin caused a dose-dependent inhibition of IGF-II-stimulated thymidine incorporation.

    In plain wordsIn lung cancer cells, hexarelin reduced DNA synthesis stimulated by IGF-II, and more so at higher doses.

    Peptide
    Hexarelin
    Outcome
    DecreaseIGF-II-stimulated thymidine incorporation
    Study

    humann: not reported in source

    CALU-1 lung carcinoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In these cells, hexarelin and EP-80317, but not ghrelin or MK-0677, caused a dose-dependent inhibition of IGF-II-stimulated thymidine incorporation and cell growth at concentrations close to their binding affinity.
  2. 02LabIn vitro (cells)Activity measurement

    In CALU-1 lung carcinoma cells, hexarelin caused a dose-dependent inhibition of IGF-II-stimulated cell growth.

    In plain wordsIn lung cancer cells, hexarelin slowed cell growth stimulated by IGF-II, and more so at higher doses.

    Peptide
    Hexarelin
    Outcome
    DecreaseIGF-II-stimulated cell growth
    Study

    humann: not reported in source

    CALU-1 lung carcinoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In these cells, hexarelin and EP-80317, but not ghrelin or MK-0677, caused a dose-dependent inhibition of IGF-II-stimulated thymidine incorporation and cell growth at concentrations close to their binding affinity.
  3. 03LabIn vitro (cells)Efficacy outcome

    In human CALU-1 lung carcinoma cells, MK-0677 did not inhibit IGF-II-stimulated thymidine incorporation.

    In plain wordsIn cells from human lung cancer, MK-0677 did not inhibit IGF-II-stimulated thymidine incorporation.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeIGF-II-stimulated thymidine incorporation
    Study

    humann: not reported in source

    Human CALU-1 lung carcinoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In these cells, hexarelin and EP-80317, but not ghrelin or MK-0677, caused a dose-dependent inhibition of IGF-II-stimulated thymidine incorporation and cell growth at concentrations close to their binding affinity.
    1 context sentence
    Summary · context
    Tyr-Ala-hexarelin binding was also present in a human lung carcinoma cell line (CALU-1).
  4. 04LabIn vitro (cells)Efficacy outcome

    In human CALU-1 lung carcinoma cells, MK-0677 did not inhibit cell growth.

    In plain wordsIn cells from human lung cancer, MK-0677 did not inhibit cell growth.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeCell growth
    Study

    humann: not reported in source

    Human CALU-1 lung carcinoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In these cells, hexarelin and EP-80317, but not ghrelin or MK-0677, caused a dose-dependent inhibition of IGF-II-stimulated thymidine incorporation and cell growth at concentrations close to their binding affinity.
    1 context sentence
    Summary · context
    Tyr-Ala-hexarelin binding was also present in a human lung carcinoma cell line (CALU-1).
  5. 05LabIn vitro (cell-free)Activity measurement

    In human lung tumor membranes, GHRP‑6 displaced the radiolabeled Tyr-Ala-hexarelin from its binding.

    In plain wordsIn lab tests with human lung tumor membranes, GHRP‑6 pushed a labeled hexarelin derivative off its binding sites.

    Peptide
    GHRP-6
    Outcome
    DecreaseDisplacement of radiolabeled Tyr-Ala-hexarelin
    Study

    humann: not reported in source

    human lung tumor membranes
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    [125I]Tyr-Ala-hexarelin binding to tumor membranes was displaced by peptidyl GHS (GHRP-6, hexarelin) and EP-80317, an hexarelin analog devoid of GH-releasing activity in vivo.
  6. 06LabIn vitro (cell-free)Activity measurement

    In human lung tumor membranes, hexarelin displaced the radiolabeled Tyr-Ala-hexarelin from its binding.

    In plain wordsIn lab tests with human lung tumor membranes, hexarelin pushed a labeled hexarelin derivative off its binding sites.

    Peptide
    Hexarelin
    Outcome
    DecreaseDisplacement of radiolabeled Tyr-Ala-hexarelin
    Study

    humann: not reported in source

    human lung tumor membranes
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    [125I]Tyr-Ala-hexarelin binding to tumor membranes was displaced by peptidyl GHS (GHRP-6, hexarelin) and EP-80317, an hexarelin analog devoid of GH-releasing activity in vivo.
  7. 07LabIn vitro (cell-free)Activity measurement

    In human lung tumor membranes, MK-0677 did not compete with radiolabeled Tyr-Ala-hexarelin binding.

    In plain wordsIn lab tests with human lung tumor membranes, MK-0677 did not compete with radiolabeled Tyr-Ala-hexarelin binding.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeRadioligand binding competition
    Study

    humann: not reported in source

    Human lung tumor membranes
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, no competition was observed in the presence of the nonpeptidyl GHS MK-0677 and the endogenous ligand of the GHS-R1a ghrelin.
    1 context sentence
    Summary · context
    [125I]Tyr-Ala-hexarelin binding to tumor membranes was displaced by peptidyl GHS (GHRP-6, hexarelin) and EP-80317, an hexarelin analog devoid of GH-releasing activity in vivo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    13 Oct 2026, 21:44 UTC

    Study results updated

  3. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.